11 -4 (28/1) 2019 — Maxmudov F.A., Latipov I.I. — THE IMMUNOPATHOGENESIS OF ATOPIC DERMATITIS AND STRATEGY OF IMMUNOTHERAPY

THE IMMUNOPATHOGENESIS OF ATOPIC DERMATITIS AND STRATEGY OF IMMUNOTHERAPY

Maxmudov F.A., Bukhara State Medical institute.

Latipov I.I. Bukhara State Medical institute.

Resume,

The immunopathogenesis of atopic dermatitis (AD) is characterized by the abnormal regulation of the cytokine profile of T-helper cells, by a greater number of highly sensitive cell IgE receptors, by the circulation of atopene- sensitive IgE and their presence in the skill. Therapeutical measures for AD include extraimmune therapy and efferent methods, the use of immune-stimulating agents, and some immunosuppressive exposures, as well as antiinflammatory, detoxifying, and antiallergic agents.

Key words: Atopic dermatitis, immunogenesis, atopens immunoglobulins, antigen presenting cells, cytoleukins, immunosuppressive agents.

First page

53

Last page

56

For citation: Maxmudov F.A., Latipov I.I. The immunopathogenesis of atopic dermatitis and strategy of immunotherapy//New Day Medicine 4(28)2019 53-56 https://cutt.ly/VbyNv35

List of References

1. Butov Yu.S. Kojnie boleznie. – Meditsina, 2014.(In Russ)
2. Shatilova N.V., Frolov E, A., Kalamkaryan A.A. Osnovnie proyavleniya immunologicheskix narusheniy u bolnix raspros- tranennimi dermatozami i ix patogeneticheskoe znachenie. // Vestnik dermatologii i venerologii – 2001; 8: 26-33. (In Russ)
3. Albanova V.I. Atopicheskiy dermatita // MRJ, razd. XI – 2010; 12: 17-21. (In Russ)
4. Andrey Sokolov. Atopicheskiy dermatit 2012; 246. (In Russ)
5. Potekaev N.S., Sergeev Yu.V. Atopicheskiy dermatit: metod. Ukazaniya. – M., 2001. (In Russ)
6. Samsova A.V., Dermatovenerologiya 2016; 6-9. (In Russ)
7. Gasich N.A., Izmenenie immunnogo statusa i optimizatsiya terapii bolnix atopicheskim dermatitom // Diss. kand. – Krasnoyarsk – 1996; (In Russ)
8. Schnyder D.S. – sit. Po Gasich N.A., 1996; (In Russ)
9. Amon E.U. Immunopathologie der atopischen Dermatitis // Dtsch. MedWschr. – 2005; 116: 120-107.
10. Chebotaryov V.V. Dermatovenerologiya Bolezni koji detey rannego vozrasta. 2016; (In Russ)
11. Van Joot J., Stolz E., Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. // Arch. Dermatol. – 2005; 123: 166-167.
12. Sowden J.M., Berth-Jones J., Ross J.S., Motley R.J. et al. Double­blind, controlled, crossover study, of cyclosporine in adults with severe refractory atopic dermatitis // Lancet – 1991; 338: 137-140.
13. Nakagawa H., Etoh J., Ishibashi Y. et al Tacrolimus ointment for atopic dermatitis // Lancet – 2009; 344: 883.
14. Meingassner J.Y., Stutz A. Immunosuppressive macrolides of the type FK506, a novel class of topical aAgents for treatment of skin diseases? // J. Invest Dermatol. – 2004; 98: 851-855.
15. Grabovskaya O.V., Usovershenstvovanie immunokorrigiruyushix metodov terapii atopicheskogo dermatita // Diss. kand. – M., 1996. (In Russ)
16. Bos J.D., Sillevis Smitt J.H. Atopic dermatitis // EADV – 2001; 7:101-114.
17. Tofte S.J., Hanifin J.M. Current management and therapy of atopic dermatitis // J. American Acad. Dermatol. -2011; 44(1): 13-16.
18. Wahn U et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children // Pediatrics – 2012; 110: 158-159.
19. Winiski A et al. Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T cell line (Jurkat) measured via RT PCR and ELISA // J. Invest. Dermatol. – 2012: 119: 347.
20. Zuberbier T et al. The ascomycin macrolactam pimecrolimus (Elidel(r), SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils // J. Allergy Clin. Immunol. – 2011: 108: 275-280.